Mobile

Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safe...

Update Il y a 4 ans
Reference: EUCTR2006-001980-41

Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safety evaluation study

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of escalating doses of imatinib in combination with hydroxyurea (HU) plus initial radiotherapy (RT) after surgery in patients with newly diagnosed glioblastoma multiforme (GBM) who are receiving or who are not receiving EIACD in phase I.

Inclusion criteria

  • Glioblastoma Multiforme

Links